An interventional study of "Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group and "Nourishing spleen and kidney with warmth" Acupuncture Group in Crohn's Disease Relapse and Inflammatory Bowel Diseases, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Recruiting at 1 site in China. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 12 that started in 2024, is one of 28 with no phase, reaches primary completion later than 48 of the 54 other live ones, and was the 68th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9
First in 2009; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 106 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 60 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 114 have an industry lead sponsor. The 10 most frequent:
Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Shanghai Institute of Acupuncture, Moxibustion and Meridian has 4 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.
Acupuncture has been proven to be an effective and safe treatment for CD. In this trial, based on previous studies, which mainly treated CD from the perspective of spleen and stomach tonification, we explored the therapeutic effect of acupuncture in treating CD from the perspective of tonifying the Shaoyang pivot mechanism to enhance the therapeutic effect.Brain-gut axis dysfunction is one of the important pathogenic mechanisms of CD. This trial attempted to explore the therapeutic targets and efficacy mechanisms of acupuncture to enhance CD by analysing brain-gut axis multi-pathway indicators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving acupuncture with the function of "harmonizing Shaoyang, nourishing spleen and kidney with warmth"
Other: "Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group
Receiving acupuncture group with the function of "nourishing spleen and kidney with warmth"
Other: "Nourishing spleen and kidney with warmth" Acupuncture Group
Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
The proportion of recurrences
Defined as CDAI \> 150 and increase ≥ 70 points, or emergency, hospitalization and surgical events due to worsening of CD conditions, or need to adjust drug to control disease condition.
Time frame: Week 52
Number of recurrences
Total number of recurrences. The median number will be counted for both groups.
Time frame: Week 52
Time of recurrences
Time to first recurrence will be counted for both groups.
Time frame: Week 52
Crohn's disease activity index (CDAI)score
The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.
Time frame: Week 0, 6, 12, 24, 36 and 52
Patient Reported Outcome (PRO2)
The outcome is measured by level of abdominal pain (visual analogue scale, VAS) and number of diarrhoea in the past week.
Time frame: Week 0, 6, 12, 24, 36 and 52
First laboratory tests
serum C-reactive protein (CRP)
Time frame: Week 0, 6, 12, 24, 36 and 52
Second laboratory tests
erythrocyte sedimentation rate (ESR)
Time frame: Week 0, 6, 12, 24, 36 and 52
Third laboratory tests
platelet count (PLT)
Time frame: Week 0, 6, 12, 24, 36 and 52
Inflammatory bowel disease questionnaire (IBDQ)
The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.
Time frame: Week 0, 12, 24, 36 and 52
Hospital anxiety and depression scale (HADS)
The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.
Time frame: Week 0, 12, 24, 36 and 52
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
The mean change in FACIT-F from baseline. The higher the score, the worse the condition. The score range from 0 to 52.
Time frame: Week 0, 12, 24, 36 and 52
Colonoscopy or small bowel MR evaluation
measured by colonoscopy (SES-CD score) or small bowel MR (MaRIA score)
Time frame: Week 0 and 52
Expectation of acupuncture treatment
measured by acupuncture treatment effectiveness expectation questionnaire
Time frame: Week 0
Blind questionnaire
measured by patients guessing their grouping
Time frame: Week 6 and 12
Effects of acupuncture on brain network connectivity properties
Gray matter structure of the brain,functional connectivity and network properties of brain networks and local activity in brain regions were measured in an attempt to analyze the correlation between changes in these indicators after acupuncture intervention and the efficacy of acupuncture.
Time frame: Week 0 and 12
Salivary cortisol
Salivary cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
α-Salivary Amylase
α-Salivary Amylase is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
Serum cortisol
Serum cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.
Time frame: Week 0 and 12
Effect of acupuncture on autonomic nervous activity
The effect of acupuncture on autonomic function was recorded by DMS300-4AL.
Time frame: Week 0 and 12
Effect of acupuncture on intestinal inflammation levels function
Intestinal inflammation levels are measured by C-reactive protein and plasma concentrations of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6.
Time frame: Week 0 and 12
Effect of acupuncture on intestinal mucosal barrier function
Intestinal mucosal barrier function are measured by concentrations of lipopolysaccharide (LPS), Diamine oxidase (DAO) and D-lactate.
Time frame: Week 0 and 12
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Dec 2028, 52 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 52 months is above that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Institute of Acupuncture, Moxibustion and Meridian